MRC1 and Lynch syndrome: The increased risk of PCa in MMR mutation carriers and in families with Lynch syndrome provide the rationale to include PCa in the Lynch syndrome tumor spectrum, which is relevant for risk estimates and surveillance recommendations in MMR mutation carriers [38].